TICKERNERD
Menu
LIVNLIVNHealthcare · Medical Devices

LIVN Stock Forecast: LivaNova PLC Price Predictions for 2026-2027

Last close, 18 Sept 2026
$78
+0.28% on the day

The 10 Wall Street analysts covering LivaNova PLC hold a median 12-month price target of $92 — +17.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.3B
Ticker Nerd rank
97 / 100
Median analyst target
$92
Analysts covering
10
Revenue$390.6M+10.8% y/y
Operating income$49.5M
Net income$108.6M
Free cash flow$35.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
−2.3%
YTD
+26.8%
1Y
+39.5%
From 52W high
−8.6%
From 52W low
+57.4%
$50
$85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LIVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LivaNova PLC on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Value
92
Revisions
89
Issuance
85
Growth
83
Quality
80
Volatility
64
Accruals
39
Size
25

Momentum (92): The shares have been drifting up relative to others.

Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LIVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LIVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$60$70$80$90$100Oct 25Jan 26Apr 26Jul 26LIVNHigh $100Median $92Low $75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $75Median $92High $100

The green dot is the last close — the median target sits +17.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
2 Sept 2026Piper SandlerReiteratesOverweight$87 → $90
5 Aug 2026NeedhamMaintainsBuy$81 → $93
5 Aug 2026NeedhamMaintainsBuy—
15 July 2026MizuhoMaintainsOutperform$90 → $95
15 July 2026MizuhoMaintainsOutperform—
1 July 2026Freedom Capital MarketsInitiatesHold—
22 June 2026KeybancMaintainsOverweight—
7 May 2026BairdMaintainsOutperform—
7 May 2026BarclaysMaintainsEqual-Weight—
7 May 2026MizuhoMaintainsOutperform—
27 Feb 2026BarclaysMaintainsEqual-Weight—
25 Feb 2026NeedhamMaintainsBuy—
9 Jan 2026BarclaysMaintainsEqual-Weight—
7 Jan 2026StifelMaintainsBuy—
19 Dec 2025KeybancInitiatesOverweight—
17 Dec 2025MizuhoMaintainsOutperform—
13 Nov 2025BairdMaintainsOutperform—
13 Nov 2025MizuhoMaintainsOutperform—
6 Nov 2025BairdMaintainsOutperform—
3 Sept 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LIVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LIVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, LivaNova PLC returned +39.5% against +16.3% for the S&P 500, dividends included.

LIVN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Oct 25Jan 26Apr 26Jul 26LIVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LIVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.5%
Analysts raising
9
Analysts cutting
0
Fundamentals

LivaNova PLC (LIVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.0×

Cheaper than 32% of US stocks

Price / sales
2.9×

Cheaper than 42% of US stocks

Price / book
3.2×

Cheaper than 30% of US stocks

EV / EBITDA
15.9×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
10.8%

Higher than 54% of US stocks

Earnings growth (YoY)
299.7%

Higher than 93% of US stocks

Gross margin
70.1%

Higher than 82% of US stocks

Operating margin
13.5%

Higher than 70% of US stocks

Net margin
12.8%

Higher than 75% of US stocks

Returns & dividend
Return on equity
15.4%

Higher than 75% of US stocks

Return on assets
5.0%

Higher than 76% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

LivaNova PLC (LIVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LivaNova PLC has a market value of $4.3B and an enterprise value of $4.1B.

  • Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 10.8% year on year.

  • Net income over the same four quarters: $188.6M, a 12.8% net margin.

  • Diluted earnings per share, trailing twelve months: $3.38.

  • Free cash flow in the twelve months to 30 June 2026: $148.3M.

  • Shares outstanding: 55.1M.

  • Trailing P/E: 23.0×; forward P/E: 16.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • LivaNova PLC employs 3,300 people — $446K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

LIVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LIVNLivaNova PLC$4.3B
97
ITGRInteger Holdings Corp.$4.4B
74
HAEHaemonetics Corp.$5.1B
99
IRTCiRhythm Holdings, Inc.$3.6B
74
TMDXTransMedics Group, Inc.$3.0B
29
NEOGNeogen Corp.$2.8B
97
AXGNAxoGen, Inc.$2.6B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LivaNova PLC — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LIVN news & analysis

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

LivaNova PLC presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item covers the company's participation in the investor conference.

Why it matters — A LIVN watcher would care because the presentation transcript offers insight into how the company communicates its business to investors at a major healthcare conference.

LivaNova Director Sells 1,650 Shares for $131,500

The Motley Fool · 11 Sept 2026neutral

LivaNova director sold 1,650 shares in a transaction valued at approximately $131,500. The shares represented 17% of the director's directly held equity stake prior to the filing.

Why it matters — An insider sale of a significant portion of a director's directly held stake is information LIVN watchers may monitor for signals about insider sentiment.

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

Business Wire · 3 Sept 2026neutral

LivaNova PLC announced it will present at two September healthcare conferences in New York City: the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 14 and the Baird 2026 Global Healthcare Conference on Sept. 15. Chief Executive Officer Vladimir Makatsaria and Chief Financial Officer Alex Shvartsburg are scheduled to attend.

Why it matters — The company's leadership is set to present to investors and analysts at two major healthcare conferences, offering a platform for LIVN to communicate its business outlook.

Artisan International Small-Mid Fund Q2 2026 Portfolio Review

Seeking Alpha · 24 Aug 2026positive

Artisan International Small-Mid Fund reported that its portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2, with NICE, Landis+Gyr and DBV Technologies as the largest detractors. LivaNova was named among the quarter's top contributors alongside Rohm and Glanbia.

Why it matters — The fund singled out LivaNova as one of its top-performing holdings for the quarter, indicating positive portfolio performance for the company during Q2.

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

Zacks Investment Research · 6 Aug 2026positive

LivaNova reported second-quarter earnings and revenues that beat estimates, supported by growth in its Cardiopulmonary and Epilepsy segments. This performance contributed to margin gains and led the company to raise its 2026 outlook.

Why it matters — A LivaNova watcher would care because better-than-expected second-quarter results, growth across Cardiopulmonary and Epilepsy, and a raised 2026 outlook point to continued strength in the company's core businesses.

FAQ

Frequently asked questions about LIVN stock

What is the LIVN stock price forecast for 2026-2027?

The 10 Wall Street analysts covering LivaNova PLC have a median 12-month price target of $92, with estimates ranging from $75 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LIVN stock a buy right now?

Of the 10 analysts covering LivaNova PLC, 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LivaNova PLC 97 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LIVN?

As at 19 Sept 2026, LivaNova PLC ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will LIVN stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +17.3% from the last close, and Ticker Nerd's factor model ranks LivaNova PLC 97 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LIVN stock forecast for 2030?

No analyst covering LivaNova PLC publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LIVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $75 to $100 over the next 12 months.

How has LIVN stock performed over the past year?

LivaNova PLC returned +39.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does LivaNova PLC do?

LivaNova PLC is a global medical technology company focused on designing, developing, manufacturing, and marketing therapies and devices for cardiac and neurological care. LivaNova PLC’s current business is organized around cardiopulmonary products, neuromodulation therapies, and advanced circulatory support, serving hospitals, clinicians, and healthcare systems with equipment used in cardiac surgery, temporary life support, and treatment of conditions such as drug-resistant epilepsy and difficult-to-treat depression.

What is the latest news on LIVN?

The most recent item we track (Seeking Alpha, 14 Sept 2026): "LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". LivaNova PLC presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item covers the company's participation in the investor conference.

Company

About LivaNova PLC.

LivaNova PLC is a global medical technology company focused on designing, developing, manufacturing, and marketing therapies and devices for cardiac and neurological care. LivaNova PLC’s current business is organized around cardiopulmonary products, neuromodulation therapies, and advanced circulatory support, serving hospitals, clinicians, and healthcare systems with equipment used in cardiac surgery, temporary life support, and treatment of conditions such as drug-resistant epilepsy and difficult-to-treat depression. The company also provides related services and support for its medical devices, making it an important supplier in specialized hospital care and life-sustaining treatment settings. Headquartered in London, England, LivaNova PLC operates across international markets and plays a role in delivering targeted medical technologies for complex clinical needs.

CEO Mr. Vladimir A. Makatsaria · 3,300 employees · United Kingdom · https://www.livanova.com